Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level652 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,842 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003298 | Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer | completed | Phase 2 | 39 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 6, 2023 | clinicaltrials |
| NCT00033657 | Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer | completed | Phase 2 | 97 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT00003237 | Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach | completed | Phase 2 | 55 | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT02935634 | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer(FRACTION-GC) | completed | Phase 2 | 190 | Bristol-Myers SquibbINDUSTRY | 9 | Jun 9, 2023 | clinicaltrials |
| NCT03918499 | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 9 | City of Hope Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT02954536 | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT04099641 | An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | completed | Phase 2 | 80 | OncXerna Theraputics, Inc.INDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT02501603 | Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer | completed | Phase 2 | 72 | Yonsei UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05025033 | Chemotherapy Combined With Apatinib and PD-1 Antibody | completed | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT00911820 | Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | completed | Phase 2 | 88 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03755440 | PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. | completed | Phase 2 | 6 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT02725424 | Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer(MATCH) | completed | Phase 2 | 180 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT02335411 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | completed | Phase 2 | 318 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2022 | clinicaltrials |
| NCT02661971 | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)(RAMSES/FLOT7) | completed | Phase 2 / Phase 3 | 180 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT01854255 | Intraperitoneal Aerosol Chemotherapy in Gastric Cancer(PIPAC-GA01) | completed | Phase 2 | 35 | Ruhr University of BochumOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03409848 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma(INTEGA) | completed | Phase 2 | 97 | AIO-Studien-gGmbHOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT01711242 | Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma | completed | Phase 2 | 208 | xie congyingOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03104283 | Apatinib for the Elderly Advanced Gastric Cancer | completed | Phase 2 | 48 | Affiliated Hospital of Qinghai UniversityOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT01896531 | A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 153 | Genentech, Inc.INDUSTRY | 11 | Mar 2, 2022 | clinicaltrials |
| NCT03130790 | Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | completed | Phase 2 / Phase 3 | 52 | ASLAN PharmaceuticalsOTHER | 8 | Feb 15, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03556345 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2 | completed | Phase 2 | 127 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 13, 2022 | clinicaltrials |
| NCT00210184 | Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer(CEPAFIRI) | completed | Phase 2 | 42 | Institut BergoniéOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00591123 | Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia | completed | Phase 2 | 38 | Translational Oncology Research InternationalOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03648879 | Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2021 | clinicaltrials |
| NCT02564367 | Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction(S-1 adjuvant) | completed | Phase 1 / Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT02845908 | POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC | completed | Phase 2 | 90 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02128243 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer(MATEO) | completed | Phase 2 | 242 | AIO-Studien-gGmbHOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT00061932 | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03083613 | Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 41 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01084330 | Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer | completed | Phase 2 | 68 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 10, 2020 | clinicaltrials |
| NCT00952003 | Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients | completed | Phase 2 | 40 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT04338438 | Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer | completed | Phase 2 | 37 | Beijing Friendship HospitalOTHER | 0 | Nov 10, 2020 | clinicaltrials |
| NCT00003862 | Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer | completed | Phase 2 | — | Radiation Therapy Oncology GroupNETWORK | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02581462 | FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer(PETRARCA) | completed | Phase 2 / Phase 3 | 81 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT00985192 | Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer | completed | Phase 2 | 49 | Translational Oncology Research InternationalOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00003748 | Irinotecan in Treating Patients With Esophageal or Stomach Cancer | completed | Phase 2 | 40 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00020761 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach | completed | Phase 2 | 51 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT02514551 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | completed | Phase 2 | 245 | Eli Lilly and CompanyINDUSTRY | 11 | Jun 17, 2020 | clinicaltrials |
| NCT01913639 | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | completed | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT02528110 | Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer | completed | Phase 2 | 100 | Wuhan UniversityOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT03606928 | mFLOT Chemotherapy as First-line Treatment in GC | completed | Phase 1 / Phase 2 | 18 | Ruijin HospitalOTHER | 1 | Mar 20, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 6, 2023source: clinicaltrials